ASCO® 2023 Insights: "TROPiCS-02 Final OS Analysis of Sacituzumab Govitecan in Pts With HR+/HER2- mBC"
By
Dana-Farber Cancer Institute
FEATURING
Sara Tolaney
By
Dana-Farber Cancer Institute
FEATURING
Sara Tolaney
Login to view comments.
Click here to Login